These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38717049)

  • 1. Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
    Kikuchi T; Takeuchi Y; Nouso K; Kariyama K; Kuwaki K; Toshimori J; Iwado S; Moriya A; Hagihara H; Takabatake H; Tada T; Yasunaka T; Sakata M; Sue M; Miyake N; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A; Otsuka M
    Liver Int; 2024 Jul; 44(7):1736-1737. PubMed ID: 38717049
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab.
    Chen B; Huang B
    Liver Int; 2024 Jul; 44(7):1735. PubMed ID: 38717059
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
    Kikuchi T; Takeuchi Y; Nouso K; Kariyama K; Kuwaki K; Toshimori J; Iwado S; Moriya A; Hagihara H; Takabatake H; Tada T; Yasunaka T; Sakata M; Sue M; Miyake N; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A; Otsuka M
    Liver Int; 2024 Jun; 44(6):1456-1463. PubMed ID: 38488749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world.
    Zhang J; Fang J; Xun Z; Xu Y; Lu X; Zhao H
    Hepatology; 2022 Oct; 76(4):E84-E85. PubMed ID: 35604038
    [No Abstract]   [Full Text] [Related]  

  • 7. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
    Tsilimigras DI; Moris D
    J BUON; 2021; 26(2):637. PubMed ID: 34077021
    [No Abstract]   [Full Text] [Related]  

  • 8. Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma.
    Allaire M; Avila MA
    Liver Int; 2024 Jun; 44(6):1276-1277. PubMed ID: 38775365
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
    Castet F; Willoughby CE; Haber PK; Llovet JM
    Clin Cancer Res; 2021 Apr; 27(7):1827-1829. PubMed ID: 33472912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Iwamoto H; Shimose S; Niizeki T; Koga H; Torimura T
    Clin Mol Hepatol; 2022 Jul; 28(3):575-579. PubMed ID: 35443321
    [No Abstract]   [Full Text] [Related]  

  • 12. Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
    Cheon J; Jung S; Kim JS; Kang B; Kim H; Chan LL; Becker L; Gaillard VE; Chan SL; Kim C; Chon HJ
    Liver Int; 2024 Aug; 44(8):1961-1970. PubMed ID: 38618972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
    Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
    Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC.
    Suchman K; Da BL
    Hepatology; 2022 Oct; 76(4):E78-E79. PubMed ID: 35503724
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series.
    Sakaguchi K; Satoh T; Kawaguchi S; Aoyama T; Asahara K; Endo S; Shirane N; Kanemoto H; Oba N; Ohno K
    Clin J Gastroenterol; 2024 Jun; 17(3):515-522. PubMed ID: 38502472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.